-
公开(公告)号：US20150190387A1
公开(公告)日：2015-07-09
申请号：US14419564
申请日：2013-08-07
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Tao Wang , John F. Kadow , Nicholas A. Meanwell , Zhongxing Zhang , Zhiwei Yin , Edward H. Ruediger , Clint A. James , Daniel H. Deon
IPC: A61K31/4545 , C07D401/14 , C07D401/06 , A61K31/454 , C07D471/04 , A61K45/06
CPC classification number: A61K31/4545 , A61K31/454 , A61K45/06 , C07D401/06 , C07D401/14 , C07D471/04
Abstract: Compounds of Formula (I), including pharmaceutically acceptable salts thereof: wherein A is selected from the group consisting of: and wherein Z is: are useful as HIV attachment inhibitors.
Abstract translation: 式（I）的化合物，包括其药学上可接受的盐：其中A选自：并且其中Z是：可用作HIV附着抑制剂。
-
公开(公告)号：US09018390B2
公开(公告)日：2015-04-28
申请号：US13919027
申请日：2013-06-17
Applicant: Bristol-Myers Squibb Company
Inventor： Carol Bachand , Makonen Belema , Daniel H. Deon , Andrew C. Good , Jason Goodrich , Clint A. James , Rico Lavoie , Omar D. Lopez , Alain Martel , Nicholas A. Meanwell , Van N. Nguyen , Jeffrey Lee Romine , Edward H. Ruediger , Lawrence B. Snyder , Denis R. St. Laurent , Fukang Yang , David R. Langley , Lawrence G. Hamann
IPC: C07D233/00 , C07D233/02 , A01N43/50 , A61K31/415 , C07D403/14 , A61K31/4178 , A61K31/4545 , A61K31/5377 , A61K31/695 , A61K45/06 , C07D401/14 , C07F7/10
CPC classification number: C07D403/14 , A61K31/4178 , A61K31/4545 , A61K31/5377 , A61K31/695 , A61K45/06 , C07D401/14 , C07F7/10
Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
Abstract translation: 本公开涉及用于治疗丙型肝炎病毒（HCV）感染的化合物，组合物和方法。 还公开了含有这些化合物的药物组合物和使用这些化合物治疗HCV感染的方法。
-
公开(公告)号：US20150023913A1
公开(公告)日：2015-01-22
申请号：US13933495
申请日：2013-07-02
Applicant: Bristol-Myers Squibb Company
Inventor： Piyasena Hewawasam , Omar D. Lopez , Yong Tu , Alan Xiangdong Wang , Ningning Xu , John F. Kadow , Nicholas A. Meanwell , Samayamuthula Venkata Satya Arun Kumar Gupta , Indasi J. Gopi Kumar , Suresh Kumar Ponugupati , Makonen Belema
IPC: A61K38/21 , A61K31/4178 , A61K31/7056 , A61K31/4245 , C07D233/64 , C07D403/14 , C07D493/08 , A61K31/4725 , C07D405/14 , A61K45/06
CPC classification number: A61K31/4178 , A61K31/402 , A61K31/4184 , A61K31/4188 , A61K31/4245 , A61K31/437 , A61K31/439 , A61K31/454 , A61K31/4545 , A61K31/4725 , A61K31/519 , A61K31/5365 , A61K31/5377 , A61K31/695 , A61K31/7056 , A61K38/2013 , A61K38/204 , A61K38/208 , A61K38/21 , A61K45/06 , C07D233/64 , C07D403/14 , C07D405/14 , C07D493/08 , A61K2300/00
Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.
-
公开(公告)号：US20150011754A1
公开(公告)日：2015-01-08
申请号：US14488990
申请日：2014-09-17
Applicant: Bristol-Myers Squibb Company
Inventor： Carol Bachand , Makonen Belema , Daniel H. Deon , Andrew C. Good , Jason Goodrich , Clint A. James , Rico Lavoie , Omar D. Lopez , Alain Martel , Nicholas A. Meanwell , Van N. Nguyen , Jeffrey Lee Romine , Edward H. Ruediger , Lawrence B. Snyder , Denis R. St. Laurent , Fukang Yang , David R. Langley , Lawrence G. Hamann
IPC: C07D413/14 , C07D401/14 , C07D233/64 , C07D403/14 , C07D405/14
CPC classification number: C07D233/64 , A61K31/4178 , A61K45/06 , C07D207/16 , C07D401/14 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07F5/025 , C07F7/0812
Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
-
45.发明授权公开(公告)号：US08906889B2
公开(公告)日：2014-12-09
申请号：US13760726
申请日：2013-02-06
Applicant: Bristol-Myers Squibb Company
Inventor： Jacob Swidorski , Nicholas A. Meanwell , Alicia Regueiro-Ren , Sing-Yuen Sit , Jie Chen , Yan Chen
CPC classification number: C07J53/002 , A61K31/58 , A61K45/06 , C07J63/008 , A61K2300/00
Abstract: Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, C-3 cycloalkenyl triterpenoids that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formulas I, II, III and IV: wherein X can be a C4-8 cycloalkyl, C4-8 cycloalkenyl, C4-9 spirocycloalkyl, C4-9 spirocycloalkenyl, C4-8 oxacycloalkyl, C4-8 dioxacycloalkyl, C6-8 oxacycloalkenyl, C6-8 dioxacycloalkenyl, C6-9 oxaspirocycloalkyl, or C6-9 oxaspirocycloalkenyl ring. These compounds are useful for the treatment of HIV and AIDS.
Abstract translation: 阐述了具有药物和生物影响特性的化合物，其药物组合物和使用方法。 特别地，具有独特抗病毒活性的C-3环烯基三萜类化合物作为HIV成熟抑制剂提供，如式I，II，III和IV化合物所示：其中X可以是C 4-8环烷基，C 4-8环烯基，C 4 -9螺环烷基，C4-9螺环烯基，C4-8氧杂环烷基，C4-8二氧杂环烷基，C6-8氧杂环烯基，C6-8二氧杂环烯基，C6-9氧杂螺环烷基或C6-9氧杂环烯烯基环。 这些化合物可用于治疗艾滋病毒和艾滋病。
-
Patent Agency Ranking
46.发明授权公开(公告)号：US08871771B2
公开(公告)日：2014-10-28
申请号：US13861804
申请日：2013-04-12
Applicant: Bristol-Myers Squibb Company
Inventor： Yasutsugu Ueda , Timothy P. Connolly , John F. Kadow , Nicholas A. Meanwell , Tao Wang , Chung-Pin H. Chen , Kap-Sun Yeung , Zhongxing Zhang , David Kenneth Leahy , Shawn K. Pack , Nachimuthu Soundararajan , Pierre Sirard , Kathia Levesque , Dominique Thoraval
IPC: A61K31/497 , C07D401/00
CPC classification number: A61K31/675 , A61K31/497 , A61K45/06 , C07D471/04 , C07F9/062 , C07F9/5728 , C07F9/65515 , C07F9/65586 , C07F9/6561
Abstract: This invention provides for prodrug Compounds I, pharmaceutical compositions thereof, and their use in treating HIV infection. wherein: X is C or N with the proviso that when X is N, R1 does not exist; W is C or N with the proviso that when W is N, R2 does not exist; V is C; E is hydrogen or a pharmaceutically acceptable salt thereof; and Y is selected from the group consisting of Also, this invention provides for intermediate Compounds II useful in making prodrug Compounds I. wherein: L and M are independently selected from the group consisting of C1-C6 alkyl, phenyl, benzyl, trialkylsilyl, -2,2,2-trichloroethoxy and 2-trimethylsilylethoxy.
Abstract translation: 本发明提供前药化合物I，其药物组合物及其在治疗HIV感染中的用途。 其中：X为C或N，条件是当X为N时，R1不存在; W为C或N，条件是当W为N时，R2不存在; V是C; E是氢或其药学上可接受的盐; 并且Y选自本发明另外，本发明提供了可用于制备前药化合物I的中间体化合物II。其中：L和M独立地选自C 1 -C 6烷基，苯基，苄基，三烷基甲硅烷基， 2,2,2-三氯乙氧基和2-三甲基甲硅烷基乙氧基。
-
47.发明申请公开(公告)号：US20130289046A1
公开(公告)日：2013-10-31
申请号：US13858624
申请日：2013-04-08
Applicant: Bristol-Myers Squibb Company
Inventor： TAO WANG , Zhongxing Zhang , Nicholas A. Meanwell , John F. Kadow , Zhiwei Yin , Qiufen May Xue , Alicia Regueiro-Ren , John D. Matiskella , Yasutsugu Ueda
IPC: A61K31/496 , A61K45/06
CPC classification number: C07D471/04 , A61K31/496 , A61K45/06 , C07D491/048
Abstract: This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.
-
公开(公告)号：US20180086793A1
公开(公告)日：2018-03-29
申请号：US15822744
申请日：2017-11-27
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Kevin W. Gillman , Jason Goodrich , Kenneth M. Boy , Yunhui Zhang , Claudio Mapelli , Michael A. Poss , Paul Michael Scola , David R. Langley , Nicholas A. Meanwell
CPC classification number: C07K7/08 , A61K38/00 , A61K38/10 , A61K45/06 , A61K51/088 , C07K7/56 , Y02A50/463
Abstract: The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
-
公开(公告)号：US09505752B2
公开(公告)日：2016-11-29
申请号：US14419559
申请日：2013-08-07
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Tao Wang , Zhongxing Zhang , John F. Kadow , Nicholas A. Meanwell , Edward H. Ruediger , Clint A. James , Daniel H. Deon , David J. Carini , Barry L. Johnson
IPC: C07D471/04 , A61K31/4545 , C07D401/06 , A61K31/454 , A61K45/06
CPC classification number: C07D471/04 , A61K31/454 , A61K31/4545 , A61K45/06 , C07D401/06
Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof: formula (I): wherein A is selected from the group consisting of: formula (II) and wherein Z is selected from the group consisting of: formula (III): and. are useful as HIV attachment inhibitors.
-
公开(公告)号：US20160152615A1
公开(公告)日：2016-06-02
申请号：US15015712
申请日：2016-02-04
Applicant: Bristol-Myers Squibb Company
Inventor： TAO WANG , Zhongxing Zhang , Nicholas A. Meanwell , John F. Kadow , Zhiwei Yin , Qiufen May Xue , Alicia Regueiro-Ren , John D. Matiskella , Yasutsugu Ueda
IPC: C07D471/04
CPC classification number: C07D471/04 , A61K31/496 , A61K45/06 , C07D491/048
Abstract: This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.
-
-
-
-
-
-
-
-
-
Search Results
59
records
(took 0.083 seconds)
